Don’t Jump to Airsupra for Asthma Rescue

April 2024

Reps will tout albuterol/budesonide (Airsupra) as the first “dual-action” rescue inhaler FDA-approved for asthma in adults.

We’re used to reaching for albuterol for quick relief.

But this new short-acting beta-agonist/inhaled corticosteroid (ICS) combo aligns with guidelines moving toward anti-inflammatory reliever (AIR) options...instead of using albuterol alone.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

Cutting-edge advice about new medications and how they fit into practice
Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

COVID-19 Be-Ready-for-Questions-About-Spring-COVID-19-Boosters
Asthma Don’t Jump to Airsupra for Asthma Rescue
Diabetes Tailor Glycemic Goals for Patients With Diabetes
Anxiety Weigh Med Options for Generalized Anxiety Disorder
Acute Pain Treat Acute Pain in Patients on Chronic Opioids
Coupons & Discounts Help Ease the Sting of Costly Meds
HIV & AIDS Sort Through HIV Pre-Exposure Prophylaxis (PrEP) Options
NatMed Spotlight Tell Patients Not to Rely on Astaxanthin for Sun Protection

Don’t Jump to Airsupra for Asthma Rescue

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Table of Contents